WUXI

WXI

N/A

NASDAQHealthcare🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 1, 2026

21d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

5 upcoming, 0 past

⭐Phase 3Next

CU-20101 treatment for Moderate to Severe Glabellar Striae Phase 3 Results Expected

Mar 1, 2026CU-20101 treatment for Moderate to Severe Glabellar Striae554

Primary completion for CU-20101 treatment for Moderate to Severe Glabellar Striae trial (NCT06585696) in Glabellar Frown Lines

Source

⭐Phase 3

Drug: 5 mg BGM0504 Administered SC Phase 3 Results Expected

Mar 20, 2026Drug: 5 mg BGM0504 Administered SC537

Primary completion for Drug: 5 mg BGM0504 Administered SC trial (NCT06716216) in Type 2 Diabetes Mellitus (T2DM)

Source

⭐Phase 3

Semaglutide Phase 3 Results Expected

Jul 31, 2026Semaglutide477

Primary completion for Semaglutide trial (NCT07064486) in Type 2 Diabetes (T2DM)

Source

⭐Phase 3

BGM0504 Phase 3 Results Expected

Jul 31, 2026BGM0504477

Primary completion for BGM0504 trial (NCT07064486) in Type 2 Diabetes (T2DM)

Source

⭐Phase 3

Mesenchymal Stem Cells Phase 3 Results Expected

December 2026~Mesenchymal Stem Cells520

Primary completion for Mesenchymal Stem Cells trial (NCT06570291) in Knee Osteoarthritis

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

5 mg BGM0504 injection

Phase 3

Overweight or Obesity

Guideline-directed medical therapy (GDMT) for heart failure

Phase 3

Pulmonary Hypertension

Mesenchymal Stem Cells

Phase 3

Knee Osteoarthritis

CU-20101 treatment for Moderate to Severe Glabellar Striae

Phase 3

Glabellar Frown Lines

CU-40102 Spray

Phase 3

AGA

Lidocaine tetracaine cream

Phase 3

Analgesia

Semaglutide

Phase 3

Type 2 Diabetes (T2DM)

BGM0504

Phase 3

Obesity

Drug: 5 mg BGM0504 Administered SC

Phase 3

Type 2 Diabetes Mellitus (T2DM)

Drug: : 10 mg BGM0504 Administered SC

Phase 3

Type 2 Diabetes Mellitus (T2DM)

D3S-001

Phase 2

KRAS P.G12C

CU-20401

Phase 2

Safety

Subcutaneous injection of CU-20401

Phase 2

Efficacy and Safety

BGM0504 Administered SC

Phase 2

Type 2 Diabetes

D3S-002

Phase 2

Advanced Solid Tumors With MAPK Pathway Mutations

Drug Name	Phase	Indication	Designations
5 mg BGM0504 injection	Phase 3	Overweight or Obesity	-
Guideline-directed medical therapy (GDMT) for heart failure	Phase 3	Pulmonary Hypertension	-
Mesenchymal Stem Cells	Phase 3	Knee Osteoarthritis	-
CU-20101 treatment for Moderate to Severe Glabellar Striae	Phase 3	Glabellar Frown Lines	-
CU-40102 Spray	Phase 3	AGA	-
Lidocaine tetracaine cream	Phase 3	Analgesia	-
Semaglutide	Phase 3	Type 2 Diabetes (T2DM)	-
BGM0504	Phase 3	Obesity	-
Drug: 5 mg BGM0504 Administered SC	Phase 3	Type 2 Diabetes Mellitus (T2DM)	-
Drug: : 10 mg BGM0504 Administered SC	Phase 3	Type 2 Diabetes Mellitus (T2DM)	-
D3S-001	Phase 2	KRAS P.G12C	-
CU-20401	Phase 2	Safety	-
Subcutaneous injection of CU-20401	Phase 2	Efficacy and Safety	-
BGM0504 Administered SC	Phase 2	Type 2 Diabetes	-
D3S-002	Phase 2	Advanced Solid Tumors With MAPK Pathway Mutations	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

WXI News